NASDAQ: CELG Health Care Sector. Biotech & Pharma Industry. 5 Year Return 7%. 1 Year Return 11%. 2021 YTD Return 100%.
The 52 Week Low is $5.18 set on Fri, Feb 28, 2020.
The 52 Week High is $13.83 set on Tue, Jun 2, 2020.
The All-Time High is $0.00 set on Wed, Dec 31, 1969.
Earnings Per Share
Price To Earnings Ratio
Dividend Yield
Dividend Rate
Ex-Dividend Date
Dividend Payment Date
Dividend Frequency
Dividend History
Celgene trades on the NASDAQ. CELG's market cap is --.
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.
For Starters
Track your portfolio and more.
